Literature DB >> 22019500

Acid suppression increases rates of Barrett's esophagus and esophageal injury in the presence of duodenal reflux.

Ayman O Nasr1, Mary F Dillon, Susie Conlon, Paul Downey, Gang Chen, Adrian Ireland, Eamon Leen, David Bouchier-Hayes, Thomas N Walsh.   

Abstract

BACKGROUND: The contribution of gastric acid to the toxicity of alkaline duodenal refluxate on the esophageal mucosa is unclear. This study compared the effect of duodenal refluxate when acid was present, decreased by proton pump inhibitors (PPI), or absent.
METHODS: We randomized 136 Sprague-Dawley rats into 4 groups: group 1 (n = 33) were controls; group 2 (n = 34) underwent esophagoduodenostomy promoting "combined reflux"; group 3 (n = 34) underwent esophagoduodenostomy and PPI treatment to decrease acid reflux; and group 4, the 'gastrectomy' group (n = 35) underwent esophagoduodenostomy and total gastrectomy to eliminate acid in the refluxate. Esophaguses were examined for inflammatory, Barrett's, and other histologic changes, and expression of proliferative markers Ki-67, proliferating cell nuclear antigen (PCNA), and epidermal growth factor receptor (EGFR).
RESULTS: In all reflux groups, the incidence of Barrett's mucosa was greater when acid was suppressed (group C, 62%; group D, 71%) than when not suppressed (group B, 27%; P = 0.004 and P < .001). Erosions were more frequent in the PPI and gastrectomy groups than in the combined reflux group. Edema (wet weight) and ulceration was more frequent in the gastrectomy than in the combined reflux group. Acute inflammatory changes were infrequent in the PPI group (8%) compared with the combined reflux (94%) or gastrectomy (100%) groups, but chronic inflammation persisted in 100% of the PPI group. EGFR levels were greater in the PPI compared with the combined reflux group (P = .04). Ki-67, PCNA, and combined marker scores were greater in the gastrectomy compared with the combined reflux group (P = .006, P = .14, and P < .001).
CONCLUSION: Gastric acid suppression in the presence of duodenal refluxate caused increased rates of inflammatory changes, intestinal metaplasia, and molecular proliferative activity. PPIs suppressed acute inflammatory changes only, whereas chronic inflammatory changes persisted. Copyright Â
© 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22019500     DOI: 10.1016/j.surg.2011.08.021

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

Review 1.  Animal Models of Barrett's Esophagus and Esophageal Adenocarcinoma-Past, Present, and Future.

Authors:  Harit Kapoor; Kush Raj Lohani; Tommy H Lee; Devendra K Agrawal; Sumeet K Mittal
Journal:  Clin Transl Sci       Date:  2015-07-27       Impact factor: 4.689

Review 2.  Do proton pump inhibitors protect against cancer progression in GERD?

Authors:  Tomoharu Miyashita; Furhawn A Shah; John W Harmon; Guy P Marti; Daisuke Matsui; Koichi Okamoto; Isamu Makino; Hironori Hayashi; Katsunobu Oyama; Hisatoshi Nakagawara; Hidehiro Tajima; Hideto Fujita; Hiroyuki Takamura; Manabu Murakami; Itasu Ninomiya; Hirohisa Kitagawa; Sachio Fushida; Takashi Fujimura; Tetsuo Ohta
Journal:  Surg Today       Date:  2012-10-31       Impact factor: 2.549

3.  Durable Flap-Valve Mitigation of Duodenogastric Reflux,  Remnant Gastritis and Dumping Syndrome Following Billroth I Reconstruction.

Authors:  Yoshiyuki Hoya; Tetsuya Taki; Atsushi Watanabe; Tomoko Nakayoshi; Tomoyoshi Okamoto; Norio Mitsumori; Katsuhiko Yanaga
Journal:  J Gastrointest Surg       Date:  2015-12-14       Impact factor: 3.452

4.  Fundoplication is superior to medical therapy for Barrett's esophagus disease regression and progression: a systematic review and meta-analysis.

Authors:  H Wilson; V Mocanu; W Sun; J Dang; U Jogiat; J Kung; N Switzer; C Wong; S Karmali
Journal:  Surg Endosc       Date:  2021-05-18       Impact factor: 4.584

Review 5.  Proton Pump Inhibitors: The Culprit for Barrett's Esophagus?

Authors:  Omran Alsalahi; Anca D Dobrian
Journal:  Front Oncol       Date:  2015-01-09       Impact factor: 6.244

Review 6.  Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis.

Authors:  Qiang Hu; Tian-Tian Sun; Jie Hong; Jing-Yuan Fang; Hua Xiong; Stephen J Meltzer
Journal:  PLoS One       Date:  2017-01-10       Impact factor: 3.240

7.  Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin-αv trafficking.

Authors:  David O Prichard; Anne Marie Byrne; James O Murphy; John V Reynolds; Jacintha O'Sullivan; Ronan Feighery; Brendan Doyle; Osama Sharaf Eldin; Stephen P Finn; Aoife Maguire; Deirdre Duff; Dermot P Kelleher; Aideen Long
Journal:  J Cell Mol Med       Date:  2017-09-22       Impact factor: 5.310

8.  The effect of laparoscopic fundoplication in therapy of Barrett's esophagus.

Authors:  René Aujeský; Cestmír Neoral; Radek Vrba; Martin Stašek; Katherine Vomáčková
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-04-01       Impact factor: 1.195

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.